Cipla fell 2.25% to Rs 461.15 after the company offered updates on USFDA inspection at its manufacturing facility in Goa.
The drug maker informed has informed that that the United States Food and Drug Administration (USFDA) has classified the inspection conducted at its Goa manufacturing facility from 16-27 September 2019 as Official Action Indicated (OAI).
The company does not believe that this will have any material impact on the US business at this stage. The company has a strong track record of maintaining the highest standard of compliance and will work closely with the agency to comprehensively address the observations received.
Cipla is a global pharmaceutical company focused on complex generics. The company's strengths lay in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS) segments.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
